Latest Medical Device Market News

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

ImpediMed Limited reported a record quarter for its SOZO device sales with $6.3 million in contracts, supported by expanded US reimbursement coverage and new funding. Despite stable revenue, the company’s cost-cutting and strategic moves position it well for growth in FY26.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

Cochlear Limited has secured FDA approval for its latest Nucleus Nexa System and Kanso 3 sound processors, setting the stage for a US market debut in early FY26.

Osteopore Limited has announced a $20 million convertible notes offering aimed at bolstering its capital for ongoing operations and future projects. The highly speculative offer targets sophisticated investors and underscores the company’s strategic funding approach amid competitive medical device markets.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Hydrix Limited reports back-to-back profitable quarters driven by strong margins and cost efficiencies, underpinned by a robust $40 million sales opportunity pipeline in cardiac and medtech sectors.